Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Barry HockScientific Officer
Honorary Research Fellow

BSc(Hons), PhD(Otago)

Email barry.hock@otago.ac.nz
Tel 64 3 364 0579

^ Top of page

Publications

Prebble, H., Cross, S., Marks, E., Healy, J. L., Searle, E., Aamir, R., Butler, A., Roake, J., Hock, B., Anderson, N., & Gieseg, S. P. (2018). Induced macrophage activation in live excised atherosclerotic plaque. Immunobiology. Advance online publication. doi: 10.1016/j.imbio.2018.03.002

Hock, B. D., McKenzie, J. L., Goddard, L., Smith, S. M., McEntyre, C. J., & Keating, P. E. (2018). Discrimination of anti-drug antibodies with neutralizing capacity in infliximab-and adalimumab-treated patients: Comparison of the homogeneous mobility shift assay and the affinity capture and elution assay. Therapeutic Drug Monitoring, 40(6), 705-715. doi: 10.1097/FTD.0000000000000553

Hock, B. D., Mulholland, K. S., Ganly, P., McKenzie, J. L., Pearson, J. F., & Macpherson, S. A. (2018). Impact of increased access to novel agents on the survival of multiple myeloma patients treated at a single New Zealand centre. Internal Medicine Journal. Advance online publication. doi: 10.1111/imj.14155

Barclay, M. L., Karim, S., Helms, E. T. J., Keating, P. E., Hock, B., Stamp, L. K., & Schultz, M. (2018). Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays. Internal Medicine Journal. Advance online publication. doi: 10.1111/imj.14064

Buss, L., Currie, M., Ang, A., Hock, B., & Dachs, G. (2018). Exercise reduces hypoxia and increases perfusion in tumours from mice with melanoma. Proceedings of the New Zealand Society for Oncology (NZSO) Conference. Retrieved from http://www.nzsoncology.org.nz/

Journal - Research Article

Prebble, H., Cross, S., Marks, E., Healy, J. L., Searle, E., Aamir, R., Butler, A., Roake, J., Hock, B., Anderson, N., & Gieseg, S. P. (2018). Induced macrophage activation in live excised atherosclerotic plaque. Immunobiology. Advance online publication. doi: 10.1016/j.imbio.2018.03.002

Barclay, M. L., Karim, S., Helms, E. T. J., Keating, P. E., Hock, B., Stamp, L. K., & Schultz, M. (2018). Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays. Internal Medicine Journal. Advance online publication. doi: 10.1111/imj.14064

Hock, B. D., Mulholland, K. S., Ganly, P., McKenzie, J. L., Pearson, J. F., & Macpherson, S. A. (2018). Impact of increased access to novel agents on the survival of multiple myeloma patients treated at a single New Zealand centre. Internal Medicine Journal. Advance online publication. doi: 10.1111/imj.14155

Hock, B. D., McKenzie, J. L., Goddard, L., Smith, S. M., McEntyre, C. J., & Keating, P. E. (2018). Discrimination of anti-drug antibodies with neutralizing capacity in infliximab-and adalimumab-treated patients: Comparison of the homogeneous mobility shift assay and the affinity capture and elution assay. Therapeutic Drug Monitoring, 40(6), 705-715. doi: 10.1097/FTD.0000000000000553

Shchepetkina, A. A., Hock, B. D., Miller, A., Kennedy, M. A., & Gieseg, S. P. (2017). Effect of 7,8-dihydroneopterin mediated CD36 down regulation and oxidant scavenging on oxidised low-density lipoprotein induced cell death in human macrophages. International Journal of Biochemistry & Cell Biology, 87, 27-33. doi: 10.1016/j.biocel.2017.03.017

Hock, B. D., Macpherson, S. A., & McKenzie, J. L. (2017). Idelalisib and caffeine reduce suppression of T cell responses mediated by activated chronic lymphocytic leukemia cells. PLoS ONE, 12(3), e0172858. doi: 10.1371/journal.pone.0172858

Seddon, A., Hock, B., Miller, A., Frei, L., Pearson, J., McKenzie, J., Simcock, J., & Currie, M. (2016). Cutaneous squamous cell carcinomas with markers of increased metastatic risk are associated with elevated numbers of neutrophils and/or granulocytic myeloid derived suppressor cells. Journal of Dermatological Science, 83(2), 124-130. doi: 10.1016/j.jdermsci.2016.04.013

Hock, B. D., McIntosh, N. D., McKenzie, J. L., Pearson, J. F., Simcock, J. W., & Macpherson, S. A. (2016). Incidence of cutaneous squamous cell carcinoma in a New Zealand population of chronic lymphocytic leukaemia patients. Internal Medicine Journal, 46(12), 1414-1421. doi: 10.1111/imj.13261

Hock, B. D., Stamp, L. K., Hayman, M. W., Keating, P. E., Helms, E. T. J., & Barclay, M. L. (2016). Development of an ELISA-based competitive binding assay for the analysis of drug concentration and anti-drug antibody levels in patients receiving adalimumab or infliximab. Therapeutic Drug Monitoring, 38(1), 32-41. doi: 10.1097/ftd.0000000000000229

Hock, B. D., McKenzie, J. L., Cross, N. B., & Currie, M. J. (2015). Dynamic changes in myeloid derived suppressor cell subsets following renal transplant: A prospective study. Transplant Immunology, 32(3), 164-171. doi: 10.1016/j.trim.2015.05.001

Hock, B. D., Macpherson, S. A., Fernyhough, L. J., & McKenzie, J. L. (2014). Chronic lymphocytic leukemia cells become both activated and immunosuppressive following interaction with CD3 and CD28 stimulated PBMC. Leukemia Research, 38(10), 1217-1223. doi: 10.1016/j.leukres.2014.06.004

Fernyhough, L. J., Hock, B. D., Taylor, J., Pearson, J., & Ganly, P. (2013). Survival of myeloma patients following the introduction of thalidomide as a second-line therapy: A retrospective study at a single New Zealand centre. Internal Medicine Journal, 43(2), 130-137. doi: 10.1111/j.1445-5994.2012.02819.x

Hock, B. D., Fernyhough, L. J., Gough, S. M., & McKenzie, J. L. (2013). Clinical significance of plasma levels of soluble CD40 in patients with chronic lymphocytic leukemia. Open Journal of Blood Diseases, 3(1), 1-5. doi: 10.4236/ojbd.2013.31001

Fernyhough, L. J., Buchan, V. A., McArthur, L. T., & Hock, B. D. (2013). Relative recovery of haematopoietic stem cell products after cryogenic storage of up to 19 years. Bone Marrow Transplantation, 48(1), 32-35. doi: 10.1038/bmt.2012.97

Hock, B. D., Taylor, K. G., Cross, N. B., Kettle, A. J., Hampton, M. B., & McKenzie, J. L. (2012). Effect of activated human polymorphonuclear leucocytes on T lymphocyte proliferation and viability. Immunology, 137(3), 249-258. doi: 10.1111/imm.12004

Hock, B. D., Mackenzie, K. A., Cross, N. B., Taylor, K. G., Currie, M. J., Robinson, B. A., Simcock, J. W., & McKenzie, J. L. (2012). Renal transplant recipients have elevated frequencies of circulating myeloid-derived suppressor cells. Nephrology Dialysis Transplantation, 27(1), 402-410. doi: 10.1093/ndt/gfr264

Geertsema, L., Lucas, S. J. E., Cotter, J. D., Hock, B., McKenzie, J., & Fernyhough, L. J. (2011). The cardiovascular risk factor, soluble CD40 ligand (CD154), but not soluble CD40, is lowered by ultra-endurance exercise in athletes. British Journal of Sports Medicine, 45(1), 42-45. doi: 10.1136/bjsm.2008.051896

MacKenzie, K. A., Miller, A. P., Hock, B. D., Gardner, J., Simcock, J. W., Roake, J. A., Dachs, G. U., Robinson, B. A., & Currie, M. J. (2011). Angiogenesis and host immune response contribute to the aggressive character of non-melanoma skin cancers in renal transplant recipients. Histopathology, 58(6), 875-885. doi: 10.1111/j.1365-2559.2011.03845.x

Hock, B. D., McKenzie, J. L., McArthur, L., Tansley, S., Taylor, K. G., & Fernyhough, L. J. (2010). CD38 as a prognostic marker in chronic lymphocytic leukaemia at a single New Zealand centre: Patient survival in comparison to age and sex matched population data. Internal Medicine Journal, 40(12), 842-849. doi: 10.1111/j.1445-5994.2009.02135.x

Hock, B. D., Fernyhough, L. J., Gough, S. M., Steinkasserer, A., Cox, A. G., & McKenzie, J. L. (2009). Release and clinical significance of soluble CD83 in chronic lymphocytic leukemia. Leukemia Research, 33(8), 1089-1095. doi: 10.1016/j.leukres.2009.01.001

Saunderson, S. C., Schuberth, P. C., Dunn, A. C., Miller, L., Hock, B. D., MacKay, P. A., … Jack, R. W., & McLellan, A. D. (2008). Induction of exosome release in primary B cells stimulated via CD40 and the IL-4 receptor. Journal of Immunology, 180(12), 8146-8152.

Hock, B. D., McKenzie, J. L., Patton, N. W., Drayson, M., Taylor, K., Wakeman, C., … Albitar, M. (2006). Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies. Cancer, 106(10), 2148-2157.

Zinser, E., Lechmann, M., Golka, A., Hock, B., & Steinkasserer, A. (2006). Determination of the inhibitory activity and biological half-live of soluble CD83: Comparison of wild type and mutant isoforms. Immunobiology, 211, 449-453.

Hock, B. D., Drayson, M., Patton, W. N., Taylor, K., Kerr, L., McKenzie, J. L., & on behalf of the Working Party on Leukaemia in Adults. (2006). Circulating levels and clinical significance of soluble CD86 in myeloma patients. British Journal of Haematology, 133, 165-172.

Hock, B. D., O'Donnell, J. L., Taylor, K., Steinkasserer, A., McKenzie, J. L., Rothwell, A. G., & Summers, K. L. (2006). Levels of the soluble forms of CD80, CD86, and CD83 are elevated in the synovial fluid of rheumatoid arthritis patients. Tissue Antigens, 67(1), 57-60. doi: 10.1111/j.1399-0039.2005.00524.x

Hock, B. D., Roberts, G., McKenzie, J. L., Gokhale, P., Salm, N., McLellan, A. D., Patton, N. W., & Roake, J. A. (2005). Exposure to the electrofusion process can increase the immunogenicity of human cells. Cancer Immunology, Immunotherapy, 54, 880-890.

Hock, B. D., Haring, L. F., Steinkasserer, A., Taylor, K. G., Patton, W. N., & McKenzie, J. L. (2004). The soluble form of CD83 is present at elevated levels in a number of hematological malignancies. Leukemia Research, 28, 237-241.

Hock, B. D., Starling, G. C., Patton, W. N., Salm, N., Bond, K., McArthur, L. T., & McKenzie, J. L. (2004). Identification of a circulating soluble form of CD80: Levels in patients with hematological malignancies. Leukemia & Lymphoma, 45(10), 2111-2118. doi: 10.1080/10428190410001712199

Hock, B. D., McKenzie, J., Patton, W. N., Haring, L., Yang, Y., Shen, Y., … Albitar, M. (2003). The clinical significance of soluble CD86 levels in patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer, 98, 1681-1688.

Summers, K. L., Hock, B. D., McKenzie, J. L., & Hart, D. N. J. (2001). Phenotypic characterization of five dendritic cell subsets in human tonsils. American Journal of Pathology, 159, 285-295.

Hock, B. D., Kato, M., McKenzie, J., & Hart, D. N. J. (2001). A soluble form of CD83 is released from activated dendritic cells and B lymphocytes, and is detectable in normal human sera. International Immunology, 13(7), 959-967.

El Sherbini, H., Hock, B., Fearnley, D., McLellan, A., Vuckovic, S., & Hart, D. N. J. (2000). Lectin ligands on human dendritic cells and identification of a peanut agglutinin positive subset in blood. Cellular Immunology, 200, 36-44. doi: 10.1006/cimm.1999.1612

Hock, B. D., Fearnley, D. B., Boyce, A., McLellan, A. D., Sorg, R. V., Summers, K., & Hart, D. N. J. (1999). Human dendritic cells express a 95 kDa activation/differentiation antigen defined by CMRF-56. Tissue Antigens, 53(4), 320-334. doi: 10.1034/j.1399-0039.1999.530402.x

Sorg, R. V., McLellan, A. D., Hock, B. D., Fearnley, D. B., & Hart, D. N. J. (1998). Human dendritic cells express functional interleukin-7. Immunobiology, 198(5), 514-526. doi: 10.1016/S0171-2985(98)80075-2

Sorg, U. R., Morse, T. M., Patton, W. N., Hock, B. D., Angus, H. B., Robinson, B. A., Colls, B. M., & Hart, D. N. J. (1997). Hodgkin's cells express CD83, a dendritic cell lineage associated antigen. Pathology, 29(3), 294-299. doi: 10.1080/00313029700169125

Fearnley, D. B., McLellan, A. D., Mannering, S. I., Hock, B. D., & Hart, D. N. J. (1997). Isolation of human blood dendritic cells using the CMRF-44 monoclonal antibody: implications for studies on antigen-presenting cell function and immunotherapy. Blood, 89(10), 3708-3726.

Williams, L. A., Hock, B. D., & Hart, D. N. J. (1996). Human T lymphocytes and hematopoietic cell lines expression CD24-associated carbohydrate epitopes in the absence of CD24 mRNA or protein. Blood, 88(8), 3048-3055.

^ Top of page

Journal - Research Other

Hock, B. D., McKenzie, J. L., & Keenan, J. I. (2017). Helicobacter pylori outer membrane vesicles inhibit human T cell responses via induction of monocyte COX-2 expression [Short communication]. Pathogens & Disease, 75(4), ftx034. doi: 10.1093/femspd/ftx034

^ Top of page

Conference Contribution - Published proceedings: Full paper

McLellan, A. D., Sorg, R. V., Fearnley, D. B., Hock, B. D., Tiedemann, R. J., Fraser, J. R., & Hart, D. N. J. (1997). T lymphocyte mediated regulation of costimulator molecule expression of human dendritic cells. Advances in Experimental and Medical Biology. 417, (pp. 203-206). [Full Paper]

Hart, D. N., Clark, G., Dekker, J. W., Fearnley, D. B., Kato, M., Hock, B. D., McLellan, A. D., Neil, T. K., Sorg, R. V., Sorg, U. R., Summers, K., & Vuckovic, S. (1997). Dendritic cell surface molecules. A proliferating field. Advances in Experimental and Medical Biology. 417, (pp. 439-442). [Full Paper]

^ Top of page

Conference Contribution - Published proceedings: Abstract

Buss, L., Currie, M., Ang, A., Hock, B., & Dachs, G. (2018). Exercise reduces hypoxia and increases perfusion in tumours from mice with melanoma. Proceedings of the New Zealand Society for Oncology (NZSO) Conference. Retrieved from http://www.nzsoncology.org.nz/

O'Donnell, J., Liu, J., Keating, P., Hock, B., Spellerberg, M., Barclay, M., & Stamp, L. (2017). Anti-drug antibodies (ADA): Assay performance in patients treated for inflammatory bowel and rheumatic disease with biodrugs, adalimumab and infliximab. Internal Medicine Journal, 47(Suppl. 2), (pp. 15). doi: 10.1111/imj.13426

Keating, P., Zhang, M., & Hock, B. D. (2016). Measurement of anti-TNF biologics and anti-drug antibodies in the clinical laboratory. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Annual Scientific Meeting. (pp. 22). Retrieved from http://www.queenstownresearchweek.org/index.php/ascept-nz/

Keating, P., Hock, B., Barclay, M., Stamp, L., Spellerberg, M., & O'Donnell, J. (2016). Application of an ELISA based competitive binding assay to measure concentration of anti-TNF biologics and neutralising anti-drug antibodies in the clinical laboratory. European Journal of Immunology, 46(Suppl. 1), (pp. 1033). doi: 10.1002/eji.201670200

Seddon, A. R., Hock, B. D., Miller, A. P., Frei, L. P., Pearson, J. F., McKenzie, J. L., Simcock, J. W., & Currie, M. J. (2015). Neutrophils in cutaneous squamous cell carcinoma: Potential prognostic markers? New Zealand Medical Journal, 128(1421). Retrieved from https://www.nzma.org.nz/journal

Barclay, M. L., Helms, E., Hock, B., Schultz, M., & Stamp, L. K. (2014). Trough concentrations of infliximab and adalimumab, and anti-drug antibodies, correlate with drug response in inflammatory bowel disease. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and the Molecular Pharmacology of G Protein-Coupled Receptors (MPGPCR) Joint Scientific Meeting. (pp. 25). Retrieved from http://www.asceptasm.com/

Frei, L. P., Hock, B., & Simcock, J. (2014). High neutrophil count is associated with increased severity of cutaneous squamous cell carcinoma. ANZ Journal of Surgery, 84(Suppl. 1), (pp. 155). doi: 10.1111/ans.12623

Taylor, J., Fernyhough, L., Hock, B., & Ganly, P. (2011). Multiple myeloma patients treated in Christchurch, New Zealand: A retrospective analysis. Proceedings of the Inaugural International Cancer Symposium. Retrieved from http://www.wnmeds.ac.nz/cancersymposium/programme.html

^ Top of page

Conference Contribution - Poster Presentation (not in published proceedings)

Saunderson, S. C., Schuberth, P. C., Dunn, A. C., Miller, L., Hock, B. D., MacKay, P. A., … Jack, R. W., & McLellan, A. D. (2008, November). Induction of exosome release in primary B cells stimulated via CD40 and the IL-4 receptor. Poster session presented at the Medical Sciences Congress, Queenstown, New Zealand.

^ Top of page

Conference Contribution - Verbal presentation and other Conference outputs

Buss, L., Currie, M., Ang, A., Hock, B., & Dachs, G. (2018, August). T-cell distribution in melanoma from exercising mice. Verbal presentation at the Queenstown Molecular Biology (QMB) and Australasian Society for Immunology New Zealand Branch (ASI-NZ) Joint Meeting, Queenstown, New Zealand.

More publications...